{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:05Z","timestamp":1791357245109,"version":"4.3.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1093\/ijnp\/pyx038","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T03:11:00Z","timestamp":1494990660000},"page":"788-796","source":"Crossref","is-referenced-by-count":84,"title":["Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model"],"prefix":"10.1093","volume":"20","author":[{"given":"Vanja","family":"Duric","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Banasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Lepack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Adham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Gyerty\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Duman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"key\n\t\t\t\t20171001055618_CIT0001","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1016\/j.bmcl.2012.03.104","article-title":"Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3\/D2 receptors","volume":"22","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20171001055618_CIT0002","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1523\/JNEUROSCI.5074-06.2007","article-title":"Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo","volume":"27","year":"2007","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t20171001055618_CIT0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.825","article-title":"Atypical antipsychotics and polydipsia: a cause or a treatment?","volume":"22","year":"2007","journal-title":"Hum Psychopharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-009-1583-7","article-title":"Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice","volume":"206","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t20171001055618_CIT0005","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study","volume":"76","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20171001055618_CIT0006","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1017\/S1092852913000680","article-title":"Long-term effects of cariprazine exposure on dopamine receptor subtypes","volume":"19","year":"2014","journal-title":"CNS Spectr"},{"key":"key\n\t\t\t\t20171001055618_CIT0007","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.phrs.2008.09.002","article-title":"Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour","volume":"58","year":"2008","journal-title":"Pharmacol Res"},{"key":"key\n\t\t\t\t20171001055618_CIT0008","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1016\/S0924-977X(15)30701-X","article-title":"Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial","volume":"25","year":"2015","journal-title":"Eur Neuropsychopharamcol"},{"key":"key\n\t\t\t\t20171001055618_CIT0009","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20171001055618_CIT0010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","year":"2014","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20171001055618_CIT0011","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","year":"2015","journal-title":"Bipolar Disord"},{"key":"key\n\t\t\t\t20171001055618_CIT0012","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nm.2219","article-title":"A negative regulator of MAP kinase causes depressive behavior","volume":"16","year":"2010","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20171001055618_CIT0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-012-1020-7","article-title":"Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes","volume":"70","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"key\n\t\t\t\t20171001055618_CIT0014","first-page":"1","article-title":"Antipsychotics and the dopamine serotonin connection","volume":"13","year":"2015","journal-title":"Top Med Chem"},{"key":"key\n\t\t\t\t20171001055618_CIT0015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.biopsych.2012.03.003","article-title":"Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression","volume":"72","year":"2012","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20171001055618_CIT0016","article-title":"Cariprazine for the treatment of bipolar disorder","year":"2016","journal-title":"Perspect Psychiatr Care"},{"key":"key\n\t\t\t\t20171001055618_CIT0017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0022-3565(25)38490-9","article-title":"Expression and pharmacological characterization of the human D3 dopamine receptor","volume":"268","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20171001055618_CIT0018","first-page":"21","article-title":"Atypical antipsychotic medications and hyponatremia in older adults: a population-based cohort study","volume":"3","year":"2016","journal-title":"Can J Kidney Health Dis"},{"key":"key\n\t\t\t\t20171001055618_CIT0019","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [11C]-(+)-PHNO","volume":"233","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t20171001055618_CIT0020","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/npp.2008.199","article-title":"The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study","volume":"34","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20171001055618_CIT0021","first-page":"167","article-title":"The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0022","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","article-title":"Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons","volume":"20","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20171001055618_CIT0023","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","article-title":"Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents","volume":"59","year":"2011","journal-title":"Neurochem Int"},{"key":"key\n\t\t\t\t20171001055618_CIT0024","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","year":"2015","journal-title":"J Clin Psychopharmacology"},{"key":"key\n\t\t\t\t20171001055618_CIT0025","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0920-9964(12)70588-1","article-title":"Cariprazine, a D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics","volume":"136","year":"2012","journal-title":"Schizophrenia Res"},{"key":"key\n\t\t\t\t20171001055618_CIT0026","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20171001055618_CIT0027","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1073\/pnas.0708092105","article-title":"IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress","volume":"105","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20171001055618_CIT0028","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1073\/pnas.0910658107","article-title":"Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior","volume":"107","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20171001055618_CIT0029","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.mp.4000754","article-title":"Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments","volume":"5","year":"2000","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t20171001055618_CIT0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.euroneuro.2007.07.003","article-title":"Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST)","volume":"18","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0031","first-page":"2404","article-title":"Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial","volume-title":"Lancet","year":"2015","edition":"3rd"},{"key":"key\n\t\t\t\t20171001055618_CIT0032","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(98)00297-0","article-title":"Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain","volume":"351","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0033","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/npp.2010.50","article-title":"The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro","volume":"35","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20171001055618_CIT0034","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11319070-000000000-00000","article-title":"Antipsychotic-induced hyponatraemia: a systematic review of the published evidence","volume":"33","year":"2010","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t20171001055618_CIT0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","article-title":"Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO","volume":"131","year":"2011","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20171001055618_CIT0036","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF02246218","article-title":"Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine","volume":"117","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t20171001055618_CIT0037","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2015.11.016","article-title":"Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology","volume":"26","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0038","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","year":"2009","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20171001055618_CIT0039","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FBP.0000000000000070","article-title":"Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression","volume":"25","year":"2014","journal-title":"Behav Pharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2004.04.008","article-title":"Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress","volume":"155","year":"2004","journal-title":"Behav Brain Res"},{"key":"key\n\t\t\t\t20171001055618_CIT0041","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, Phase III trial","volume":"174","year":"2015","journal-title":"J Affect Disord"},{"key":"key\n\t\t\t\t20171001055618_CIT0042","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00001756-199501000-00026","article-title":"A functional test identifies dopamine agonists selective for D3 versus D2 receptors","volume":"6","year":"1995","journal-title":"Neuroreport"},{"key":"key\n\t\t\t\t20171001055618_CIT0043","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","year":"1990","journal-title":"Nature"},{"key":"key\n\t\t\t\t20171001055618_CIT0044","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1092852916000043","article-title":"Mechanism of action of cariprazine","volume":"21","year":"2016","journal-title":"CNS Spectr"},{"key":"key\n\t\t\t\t20171001055618_CIT0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0031-9384(97)00430-7","article-title":"D3 dopamine receptor-deficient mouse: evidence for reduced anxiety","volume":"63","year":"1997","journal-title":"Physiol Behav"},{"key":"key\n\t\t\t\t20171001055618_CIT0046","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejphar.2011.07.020","article-title":"In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors","volume":"668","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0047","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14737175.2013.853448","article-title":"Cariprazine, a new, orally active dopamine D2\/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression","volume":"13","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"key\n\t\t\t\t20171001055618_CIT0048","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.euroneuro.2015.12.020","article-title":"The dopamine D(3)-preferring D(2)\/D(3) dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia","volume":"26","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0049","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2009.10.068","article-title":"Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3\/D2 antagonists does not occur through the dopamine D3 receptor","volume":"627","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20171001055618_CIT0050","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis","volume":"76","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20171001055618_CIT0051","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00213-012-2896-5","article-title":"Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse","volume":"226","year":"2013","journal-title":"Psychopharmacology (Berl)"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/20\/10\/788\/20420328\/pyx038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T17:10:29Z","timestamp":1750266629000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ijnp\/article\/20\/10\/788\/3845232\/Cariprazine-Exhibits-Anxiolytic-and-Dopamine-D3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,5,22]]},"published-print":{"date-parts":[[2017,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyx038","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}